Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial

Int J Environ Res Public Health. 2022 Jun 15;19(12):7325. doi: 10.3390/ijerph19127325.

Abstract

Despite the negative influence of cannabis use on the development and prognosis of first-episode psychosis (FEP), there is little evidence on effective specific interventions for cannabis use cessation in FEP. The aim of this study was to compare the efficacy of a specific cognitive behavioral therapy (CBT) for cannabis cessation (CBT-CC) with treatment as usual (TAU) in FEP cannabis users. In this single-blind, 1-year randomized controlled trial, 65 participants were randomly assigned to CBT-CC or TAU. The primary outcome was the reduction in cannabis use severity. The CBT-CC group had a greater decrease in cannabis use severity and positive psychotic symptoms over time, and a greater improvement in functioning at post-treatment than TAU. The treatment response was also faster in the CBT-CC group, reducing cannabis use, anxiety, positive and general psychotic symptoms, and improving functioning earlier than TAU in the follow-up. Moreover, patients who stopped and/or reduced cannabis use during the follow-up, decreased psychotic symptoms and increased awareness of disease compared to those who continued using cannabis. Early intervention based on a specific CBT for cannabis cessation, may be effective in reducing cannabis use severity, in addition to improving clinical and functional outcomes of FEP cannabis users.

Keywords: cannabis use; cognitive behavioral therapy; first-episode psychosis; outcome; randomized controlled trial.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cannabis*
  • Cognitive Behavioral Therapy*
  • Humans
  • Psychotherapy, Group*
  • Psychotic Disorders* / diagnosis
  • Single-Blind Method

Grants and funding

This study was funded by the Spanish Ministry of Economy and Competitiveness through the Carlos III Health Institute (ISCIII) and the European Regional Development Fund (ERDF) (PI13/02252, PI18/01055, PI21/00713, PI19/00569).